KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Other financing activities (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Other financing activities for 16 consecutive years, with -$17.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other financing activities fell 221.43% year-over-year to -$17.0 million, compared with a TTM value of $195.0 million through Dec 2024, up 248.21%, and an annual FY2025 reading of $90.0 million, down 53.85% over the prior year.
  • Other financing activities was -$17.0 million for Q4 2024 at Thermo Fisher Scientific, down from $67.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $192.0 million in Q4 2020 and bottomed at -$98.0 million in Q1 2020.
  • Average Other financing activities over 5 years is $17.6 million, with a median of $16.0 million recorded in 2023.
  • The sharpest move saw Other financing activities soared 868.0% in 2020, then tumbled 270.0% in 2022.
  • Year by year, Other financing activities stood at $192.0 million in 2020, then plummeted by 58.85% to $79.0 million in 2021, then plummeted by 74.68% to $20.0 million in 2022, then decreased by 30.0% to $14.0 million in 2023, then crashed by 221.43% to -$17.0 million in 2024.
  • Business Quant data shows Other financing activities for TMO at -$17.0 million in Q4 2024, $67.0 million in Q3 2024, and $35.0 million in Q2 2024.